2/27
11:30 am
gpcr
Assessing Structure Therapeutics (GPCR) Valuation After Sharp Swings And A Strong 1 Year Return [Yahoo! Finance]
Low
Report
Assessing Structure Therapeutics (GPCR) Valuation After Sharp Swings And A Strong 1 Year Return [Yahoo! Finance]
2/27
11:21 am
gpcr
Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million [Yahoo! Finance]
Low
Report
Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million [Yahoo! Finance]
2/27
09:21 am
gpcr
Structure Therapeutics (GPCR) had its price target lowered by Citizens Jmp from $120.00 to $113.00. They now have a "market outperform" rating on the stock.
Low
Report
Structure Therapeutics (GPCR) had its price target lowered by Citizens Jmp from $120.00 to $113.00. They now have a "market outperform" rating on the stock.
2/26
04:22 pm
gpcr
Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights [Yahoo! Finance]
Low
Report
Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights [Yahoo! Finance]
2/26
04:02 pm
gpcr
Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
Low
Report
Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
2/25
04:14 pm
gpcr
Structure Therapeutics Stock Soars Over 200% as One Fund Adds to a $242 Million Position [Yahoo! Finance]
Low
Report
Structure Therapeutics Stock Soars Over 200% as One Fund Adds to a $242 Million Position [Yahoo! Finance]
2/19
07:17 am
gpcr
Structure Therapeutics (GPCR) Gained from Favorable Clinical Data [Yahoo! Finance]
Low
Report
Structure Therapeutics (GPCR) Gained from Favorable Clinical Data [Yahoo! Finance]
2/18
04:52 pm
gpcr
Structure Therapeutics: The Dark Horse Has Taken The Lead - But Is It Enough? [Seeking Alpha]
Low
Report
Structure Therapeutics: The Dark Horse Has Taken The Lead - But Is It Enough? [Seeking Alpha]
2/8
04:41 pm
gpcr
Assessing Structure Therapeutics (GPCR) Valuation As GSBR-1290 Advances Through Phase 2 Obesity Trials [Yahoo! Finance]
Medium
Report
Assessing Structure Therapeutics (GPCR) Valuation As GSBR-1290 Advances Through Phase 2 Obesity Trials [Yahoo! Finance]
2/3
01:37 pm
gpcr
Obesity stocks slump on Novo's underwhelming 2026 sales forecast [Yahoo! Finance Canada]
Low
Report
Obesity stocks slump on Novo's underwhelming 2026 sales forecast [Yahoo! Finance Canada]
1/31
03:15 pm
gpcr
Key deals this week: Apple, McEwen Mining, IonQ, Leidos, and more [Seeking Alpha]
Low
Report
Key deals this week: Apple, McEwen Mining, IonQ, Leidos, and more [Seeking Alpha]
1/31
01:33 am
gpcr
Structure Therapeutics (NASDAQ:GPCR) was downgraded by analysts at
Wall
Low
Report
Structure Therapeutics (NASDAQ:GPCR) was downgraded by analysts at
Wall
1/24
05:10 am
gpcr
Structure Therapeutics (NASDAQ:GPCR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Structure Therapeutics (NASDAQ:GPCR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/23
06:57 am
gpcr
Structure Therapeutics (NASDAQ:GPCR) was upgraded by analysts at The Goldman Sachs Group, Inc. to a "strong-buy" rating.
Low
Report
Structure Therapeutics (NASDAQ:GPCR) was upgraded by analysts at The Goldman Sachs Group, Inc. to a "strong-buy" rating.
1/22
11:58 am
gpcr
Structure Therapeutics (NASDAQ:GPCR) had its price target raised by analysts at JPMorgan Chase & Co. from $65.00 to $105.00. They now have an "overweight" rating on the stock.
Low
Report
Structure Therapeutics (NASDAQ:GPCR) had its price target raised by analysts at JPMorgan Chase & Co. from $65.00 to $105.00. They now have an "overweight" rating on the stock.
1/20
08:42 am
gpcr
Structure Therapeutics (NASDAQ:GPCR) had its "buy" rating reaffirmed by analysts at Guggenheim.
Medium
Report
Structure Therapeutics (NASDAQ:GPCR) had its "buy" rating reaffirmed by analysts at Guggenheim.
1/19
08:01 pm
gpcr
Structure Therapeutics (NASDAQ:GPCR) was given a new $102.00 price target on by analysts at The Goldman Sachs Group, Inc..
Low
Report
Structure Therapeutics (NASDAQ:GPCR) was given a new $102.00 price target on by analysts at The Goldman Sachs Group, Inc..
1/15
11:52 am
gpcr
Structure Therapeutics Inc. (GPCR) Has Gained Over 130% in 3 Months. Here is Why [Yahoo! Finance]
Low
Report
Structure Therapeutics Inc. (GPCR) Has Gained Over 130% in 3 Months. Here is Why [Yahoo! Finance]
1/11
04:16 pm
gpcr
Can This Stock Double Again in 2026? [Yahoo! Finance]
Low
Report
Can This Stock Double Again in 2026? [Yahoo! Finance]
1/8
09:53 am
gpcr
H.C. Wainwright Upgrades Structure Therapeutics (GPCR) on Massive Arbitrage Opportunity for Oral GLP-1 [Yahoo! Finance]
Neutral
Report
H.C. Wainwright Upgrades Structure Therapeutics (GPCR) on Massive Arbitrage Opportunity for Oral GLP-1 [Yahoo! Finance]
1/6
07:17 am
gpcr
Structure Therapeutics (NASDAQ:GPCR) had its "outperform" rating reaffirmed by analysts at BMO Capital Markets.
Low
Report
Structure Therapeutics (NASDAQ:GPCR) had its "outperform" rating reaffirmed by analysts at BMO Capital Markets.
12/22
07:26 pm
gpcr
Structure Therapeutics (GPCR) valuation check after Phase 1 obesity candidate ACCG-2671 enters first-in-human trial [Yahoo! Finance]
High
Report
Structure Therapeutics (GPCR) valuation check after Phase 1 obesity candidate ACCG-2671 enters first-in-human trial [Yahoo! Finance]
12/19
09:09 am
gpcr
Structure Therapeutics (NASDAQ:GPCR) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Structure Therapeutics (NASDAQ:GPCR) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/17
08:40 am
gpcr
Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity [Yahoo! Finance]
Low
Report
Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity [Yahoo! Finance]
12/17
08:30 am
gpcr
Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
Low
Report
Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity